Advisory Panel Discusses Expanded Indication for Avodart

Publication
Article
Oncology & Biotech NewsDecember 2010
Volume 4
Issue 12

The FDA has released briefing documents noting that the 5-alpha reductase inhibitor increases the risk of high-risk prostate cancer.

Prior to an upcoming advisory panel meeting to discuss whether GlaxoSmithKline’s Avodart (dutasteride) should receive an expanded indication as a chemopreventive for prostate cancer, the FDA has released briefing documents noting that the 5-alpha reductase inhibitor increases the risk of high-risk prostate cancer. Whatever the panel decides might affect a request from Merck to change the label on Proscar (finasteride) to reflect study findings that it reduces the rate of low-risk prostate cancer.

Related Videos
Timothy Yap, MBBS, PhD, FRCP
Kara N. Maxwell, MD, PhD
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Rohan Garje, MD
Jeffrey P. Townsend, PhD
Rohan Garje, MD
Josep Maria Piulats Rodriguez, MD, PhD
Angela Jia, MD, PhD, of University Hospitals
Rohan Garje, MD, chief, Genitourinary Medical Oncology, Baptist Health Miami Cancer Institute
Kara N. Maxwell, MD, PhD